Search

Your search keyword '"Lønning, Per E."' showing total 389 results
Start Over Author "Lønning, Per E."
389 results on '"Lønning, Per E."'

2. Demystifying BRAF Mutation Status in Colorectal Liver Metastases: A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions

Author

Margonis, Georgios A., Boerner, Thomas, Bachet, Jean-Baptiste, Buettner, Stefan, Moretto, Roberto, Andreatos, Nikolaos, Sartore-Bianchi, Andrea, Wang, Jane, Kamphues, Carsten, Gagniere, Johan, Lonardi, Sara, Løes, Inger M., Wagner, Doris, Spallanzani, Andrea, Sasaki, Kazunari, Burkhart, Richard, Pietrantonio, Filippo, Pikoulis, Emmanouil, Pawlik, Timothy M., Truant, Stéphanie, Orlandi, Armando, Pikouli, Anastasia, Pella, Nicoletta, Beyer, Katharina, Poultsides, George, Seeliger, Hendrik, Aucejo, Federico N., Kornprat, Peter, Kaczirek, Klaus, Lønning, Per E., Kreis, Martin E., Wolfgang, Christopher L., Weiss, Matthew J., Cremolini, Chiara, Benoist, Stéphane, and D’Angelica, Michael

Published
2023
Full Text
View/download PDF

5. A national precision cancer medicine implementation initiative for Norway

Author

Taskén, Kjetil, Russnes, Hege E. G., Aas, Eline, Bjørge, Line, Blix, Egil S., Enerly, Espen, Fagereng, Gro L., Flobak, Åsmund, Gilje, Bjørnar, Gjertsen, Bjørn T., Guren, Tormod K., Heix, Jutta, Hovig, Eivind, Hovland, Randi, Lønning, Per E., Meza-Zepeda, Leonardo A., Mæhle, Per M., Nilsen, Hilde L., Thoresen, Steinar Ø., Widerberg, Ketil, Smeland, Sigbjørn, and Helland, Åslaug

Published
2022
Full Text
View/download PDF

7. Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer

Author

Yndestad, Synnøve, Engebrethsen, Christina, Herencia-Ropero, Andrea, Nikolaienko, Oleksii, Vintermyr, Olav K., Lillestøl, Reidun K., Minsaas, Laura, Leirvaag, Beryl, Iversen, Gjertrud T., Gilje, Bjørnar, Blix, Egil S., Espelid, Helge, Lundgren, Steinar, Geisler, Jürgen, Aase, Hildegunn S., Aas, Turid, Gudlaugsson, Einar G., Llop-Guevara, Alba, Serra, Violeta, Janssen, Emiel A.M., Lønning, Per E., Knappskog, Stian, and Eikesdal, Hans P.

Published
2023
Full Text
View/download PDF

8. Constitutional BRCA1 Epimutations: A Key for Understanding Basal‐Like Breast and High‐Grade Serous Ovarian Cancer.

Author

Lønning, Per E., Nikolaienko, Oleksii, Knappskog, Stian, and Hitchins, Megan

Abstract

Germline pathogenic genetic variants in the BRCA1 and BRCA2 genes are the most frequent causes of familial breast and ovarian cancer. Contrasting BRCA2, epimutations in the BRCA1 gene are frequently detected in tissue from triple‐negative breast (TNBC) and high‐grade serous ovarian cancers (HGSOC). While studies over the last decade have reported BRCA1 epimutations in white blood cells (WBC) from breast and ovarian cancer patients, the potential hazard ratio for incident TNBC and HGSOC was not formally assessed until recently. Conducting a prospective nested case‐control study on women participating in the American Women's Health Initiative Study, we provided firm evidence that mosaic WBC BRCA1 epimutations, even at allele frequencies < 0.1%, are associated with a significantly increased risk of both incident HGSOC and TNBC > 5 years after WBC collection. In a second study assessing BRCA1 epimutations in WBC and matched tumor samples from TNBC, our results indicated such epimutations to be the underlying cause of around 20% of TNBC, far exceeding the percentage of cases carrying BRCA1 germline pathogenic genetic variants. We detected primary constitutional BRCA1 epimutations in tissues derived from all three germ layers. They occur independently of BRCA1 promoter haplotypes but are present on the same allele in all WBC within affected individuals. Moreover, epimutations are consistently found on the same allele in normal and tumor breast tissue as well as in WBC. This finding, together with BRCA1 epimutations detected in WBC from newborns, strongly indicates an early embryonic event with clonal expansion affecting all germ layers. Future work in the field must lead to an understanding of exactly when and how the BRCA1 epimutations occur and, most importantly, whether primary constitutional epimutations in genes other than BRCA1 may cause an elevated risk of other cancer types. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Di Leo, Angelo, Johnston, Stephen, Lee, Keun Seok, Ciruelos, Eva, Lønning, Per E, Janni, Wolfgang, O'Regan, Ruth, Mouret-Reynier, Marie-Ange, Kalev, Dimitar, Egle, Daniel, Csőszi, Tibor, Bordonaro, Roberto, Decker, Thomas, Tjan-Heijnen, Vivianne C G, Blau, Sibel, Schirone, Alessio, Weber, Denis, El-Hashimy, Mona, Dharan, Bharani, Sellami, Dalila, and Bachelot, Thomas

Published
2018
Full Text
View/download PDF

16. Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC

Author

Røsland, Gro V., Dyrstad, Sissel E., Tusubira, Deusdedit, Helwa, Reham, Tan, Tuan Zea, Lotsberg, Maria L., Pettersen, Ina K. N., Berg, Anna, Kindt, Charlotte, Hoel, Fredrik, Jacobsen, Kirstine, Arason, Ari J., Engelsen, Agnete S. T., Ditzel, Henrik J., Lønning, Per E., Krakstad, Camilla, Thiery, Jean P., Lorens, James B., Knappskog, Stian, and Tronstad, Karl J.

Published
2019
Full Text
View/download PDF

17. Supplementary Figure from Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

Author

Batalini, Felipe, primary, Gulhan, Doga C., primary, Mao, Victor, primary, Tran, Antuan, primary, Polak, Madeline, primary, Xiong, Niya, primary, Tayob, Nabihah, primary, Tung, Nadine M., primary, Winer, Eric P., primary, Mayer, Erica L., primary, Knappskog, Stian, primary, Lønning, Per E., primary, Matulonis, Ursula A., primary, Konstantinopoulos, Panagiotis A., primary, Solit, David B., primary, Won, Helen, primary, Eikesdal, Hans P., primary, Park, Peter J., primary, and Wulf, Gerburg M., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Table from Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

Author

Batalini, Felipe, primary, Gulhan, Doga C., primary, Mao, Victor, primary, Tran, Antuan, primary, Polak, Madeline, primary, Xiong, Niya, primary, Tayob, Nabihah, primary, Tung, Nadine M., primary, Winer, Eric P., primary, Mayer, Erica L., primary, Knappskog, Stian, primary, Lønning, Per E., primary, Matulonis, Ursula A., primary, Konstantinopoulos, Panagiotis A., primary, Solit, David B., primary, Won, Helen, primary, Eikesdal, Hans P., primary, Park, Peter J., primary, and Wulf, Gerburg M., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Data from A Mitochondrial Target Sequence Polymorphism in Manganese Superoxide Dismutase Predicts Inferior Survival in Breast Cancer Patients Treated with Cyclophosphamide

Author

Glynn, Sharon A., primary, Boersma, Brenda J., primary, Howe, Tiffany M., primary, Edvardsen, Hege, primary, Geisler, Stephanie B., primary, Goodman, Julie E., primary, Ridnour, Lisa A., primary, Lønning, Per E., primary, Børresen-Dale, Anne-Lise, primary, Naume, Bjorn, primary, Kristensen, Vessela N., primary, Chanock, Stephen J., primary, Wink, David A., primary, and Ambs, Stefan, primary

Published
2023
Full Text
View/download PDF

23. Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo

Author

Knappskog, Stian, Berge, Elisabet O., Chrisanthar, Ranjan, Geisler, Stephanie, Staalesen, Vidar, Leirvaag, Beryl, Yndestad, Synnøve, de Faveri, Elise, Karlsen, Bård O., Wedge, David C., Akslen, Lars A., Lilleng, Peer K., Løkkevik, Erik, Lundgren, Steinar, Østenstad, Bjørn, Risberg, Terje, Mjaaland, Ingvild, Aas, Turid, and Lønning, Per E.

Published
2015
Full Text
View/download PDF

25. White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk

Author

Lønning, Per E., Berge, Elisabet O., Bjørnslett, Merete, Minsaas, Laura, Chrisanthar, Ranjan, Høberg-Vetti, Hildegunn, Dulary, Cécile, Busato, Florence, Bjørneklett, Silje, Eriksen, Christine, Kopperud, Reidun, Axcrona, Ulrika, Davidson, Ben, Bjørge, Line, Evans, D. Gareth, Howell, Anthony, Salvesen, Helga B., Janszky, Imre, Hveem, Kristian, Romundstad, Pål R., Vatten, Lars J., Tost, Jörg, Dørum, Anne, and Knappskog, Stian

Published
2018
Full Text
View/download PDF

27. APOBEC3A /Bdeletion polymorphism and endometrial cancer risk

Author

Sofiyeva, Nigar, primary, Krakstad, Camilla, additional, Halle, Mari K., additional, O'Mara, Tracy A., additional, Romundstad, Pål, additional, Hveem, Kristian, additional, Vatten, Lars, additional, Lønning, Per E., additional, Gansmo, Liv B., additional, and Knappskog, Stian, additional

Published
2022
Full Text
View/download PDF

29. Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

Author

Batalini, Felipe, primary, Gulhan, Doga C., additional, Mao, Victor, additional, Tran, Antuan, additional, Polak, Madeline, additional, Xiong, Niya, additional, Tayob, Nabihah, additional, Tung, Nadine M., additional, Winer, Eric P., additional, Mayer, Erica L., additional, Knappskog, Stian, additional, Lønning, Per E., additional, Matulonis, Ursula A., additional, Konstantinopoulos, Panagiotis A., additional, Solit, David B., additional, Won, Helen, additional, Eikesdal, Hans P., additional, Park, Peter J., additional, and Wulf, Gerburg M., additional

Published
2022
Full Text
View/download PDF

32. Demystifying BRAFMutation Status in Colorectal Liver Metastases

Author

Margonis, Georgios A., Boerner, Thomas, Bachet, Jean-Baptiste, Buettner, Stefan, Moretto, Roberto, Andreatos, Nikolaos, Sartore-Bianchi, Andrea, Wang, Jane, Kamphues, Carsten, Gagniere, Johan, Lonardi, Sara, Løes, Inger M., Wagner, Doris, Spallanzani, Andrea, Sasaki, Kazunari, Burkhart, Richard, Pietrantonio, Filippo, Pikoulis, Emmanouil, Pawlik, Timothy M., Truant, Stéphanie, Orlandi, Armando, Pikouli, Anastasia, Pella, Nicoletta, Beyer, Katharina, Poultsides, George, Seeliger, Hendrik, Aucejo, Federico N., Kornprat, Peter, Kaczirek, Klaus, Lønning, Per E., Kreis, Martin E., Wolfgang, Christopher L., Weiss, Matthew J., Cremolini, Chiara, Benoist, Stéphane, and D’Angelica, Michael

Published
2023
Full Text
View/download PDF

33. The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians

Author

Knappskog, Stian, Bjørnslett, Merete, Myklebust, Line M., Huijts, Petra E.A., Vreeswijk, Maaike P., Edvardsen, Hege, Guo, Yongli, Zhang, Xuemei, Yang, Ming, Ylisaukko-oja, Sanna K., Alhopuro, Pia, Arola, Johanna, Tollenaar, Rob A.E.M., van Asperen, Christi J., Seynaeve, Caroline, Staalesen, Vidar, Chrisanthar, Ranjan, Løkkevik, Erik, Salvesen, Helga B., Evans, D. Gareth, Newman, William G., Lin, Dongxin, Aaltonen, Lauri A., Børresen-Dale, Anne-Lise, Tell, Grethe S., Stoltenberg, Camilla, Romundstad, Pål, Hveem, Kristian, Lillehaug, Johan R., Vatten, Lars, Devilee, Peter, Dørum, Anne, and Lønning, Per E.

Published
2011
Full Text
View/download PDF

35. Additional file 2 of Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy

Author

Venizelos, Andreas, Engebrethsen, Christina, Deng, Wei, Geisler, Jürgen, Geisler, Stephanie, Iversen, Gjertrud T., Aas, Turid, Aase, Hildegunn S., Seyedzadeh, Manouchehr, Steinskog, Eli Sihn, Myklebost, Ola, Nakken, Sigve, Vodak, Daniel, Hovig, Eivind, Meza-Zepeda, Leonardo A., Lønning, Per E., Knappskog, Stian, and Eikesdal, Hans P.

Abstract

Additional file 2. Study Protocol.

Published
2022
Full Text
View/download PDF

36. Additional file 4 of Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy

Author

Venizelos, Andreas, Engebrethsen, Christina, Deng, Wei, Geisler, Jürgen, Geisler, Stephanie, Iversen, Gjertrud T., Aas, Turid, Aase, Hildegunn S., Seyedzadeh, Manouchehr, Steinskog, Eli Sihn, Myklebost, Ola, Nakken, Sigve, Vodak, Daniel, Hovig, Eivind, Meza-Zepeda, Leonardo A., Lønning, Per E., Knappskog, Stian, and Eikesdal, Hans P.

Abstract

Additional file 4: Table S1. Baseline characteristics. Table S2a. 6 most common serious adverse event (grade 2 or more). Table S2b. 8 most common adverse event (any grade). Table S3. Response to neoadjuvant epirubicin and docetaxel in stage II-III breast cancers, and outcome at surgery. Table S4. Treatment response. Table S5a. Pretreatment mutations and prediction to epirubicin treatment. Table S5b. Pretreatment mutations and prediction to docetaxel treatment. Table S6. Mutations in pretreatment biopsies and prediction to epirubicin treatment. Table S7. Mutations in post-epirubicin biopsies and prediction to docetaxel treatment.

Published
2022
Full Text
View/download PDF

37. Additional file 3 of Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy

Author

Venizelos, Andreas, Engebrethsen, Christina, Deng, Wei, Geisler, Jürgen, Geisler, Stephanie, Iversen, Gjertrud T., Aas, Turid, Aase, Hildegunn S., Seyedzadeh, Manouchehr, Steinskog, Eli Sihn, Myklebost, Ola, Nakken, Sigve, Vodak, Daniel, Hovig, Eivind, Meza-Zepeda, Leonardo A., Lønning, Per E., Knappskog, Stian, and Eikesdal, Hans P.

Abstract

Additional file 3: Figure S1. CONSORT diagram for the Dose-Dense trial. Figure S2. Survival in the Dose-Dense trial after a minimum follow-up of five years or until death. Figure S3. Average sequencing coverage for each sample subject to whole exome sequencing (WES). Figure S4. Average sequencing coverage for each pretreatment tumor sample subject to amplicon-based sequencing. Figure S5. Oncoplot depicting the frequency of mutations in tumor samples undergoing whole exome sequencing (WES). Figure S6. Merged overview of copy number alterations (CNAs) in the sample set. Figure S7. Scatter plot showing Pearson correlation between copy number alterations (CNAs) and tumor mutation burden. Figure S8. Estimated contribution of mutational processes for each of the patients according to the classification by COSMIC. Figure S9. Graphical representation of clonal evolution from the pretreatment setting to post-epirubicin and post-docetaxel. Figure S10. Circos plots, coxcomb plots and heatmaps illustrating copy number logRs and mutation rVAFs pretreatment, post-epirubicin and post-docetaxel.

Published
2022
Full Text
View/download PDF

38. Additional file 1 of Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy

Author

Venizelos, Andreas, Engebrethsen, Christina, Deng, Wei, Geisler, Jürgen, Geisler, Stephanie, Iversen, Gjertrud T., Aas, Turid, Aase, Hildegunn S., Seyedzadeh, Manouchehr, Steinskog, Eli Sihn, Myklebost, Ola, Nakken, Sigve, Vodak, Daniel, Hovig, Eivind, Meza-Zepeda, Leonardo A., Lønning, Per E., Knappskog, Stian, and Eikesdal, Hans P.

Abstract

Additional file 1. The Dose Dense Trial (Methods and Results) and Sequencing approaches.

Published
2022
Full Text
View/download PDF

39. APOBEC3A/B deletion polymorphism and endometrial cancer risk.

Author

Sofiyeva, Nigar, Krakstad, Camilla, Halle, Mari K., O'Mara, Tracy A., Romundstad, Pål, Hveem, Kristian, Vatten, Lars, Lønning, Per E., Gansmo, Liv B., and Knappskog, Stian

Subjects
ENDOMETRIAL cancer, DISEASE risk factors, LINKAGE disequilibrium, ENDOMETRIAL hyperplasia
Abstract

Background: A common 30 kb deletion affecting the APOBEC3A and APOBEC3B genes has been linked to increased APOBEC activity and APOBEC‐related mutational signatures in human cancers. The role of this deletion as a cancer risk factor remains controversial. Materials and Methods: We genotyped the APOBEC3A/B deletion in a sample of 1,470 Norwegian endometrial cancer cases and compared to 1,918 healthy controls. For assessment across Caucasian populations, we mined genotypes of the SNP rs12628403, which is in strong linkage disequilibrium with the deletion, in a GWAS dataset of 4,274 cases and 18,125 healthy controls, through the ECAC consortium. Results: We found the APOBEC3A/B deletion variant to be significantly associated with reduced risk of endometrial cancer among Norwegian women (OR = 0.75; 95% CI = 0.62–0.91; p = 0.003; dominant model). Similar results were found in the subgroup of endometrioid endometrial cancer (OR = 0.64; 95% CI = 0.51–0.79; p = 3.6 × 10−5; dominant model). The observed risk reduction was particularly strong among individuals in the range of 50–60 years of age (OR = 0.51; 95% CI = 0.33–0.78; p = 0.002; dominant model). In the different populations included in the ECAC dataset, the ORs varied from 0.85 to 1.05. Although five out of six populations revealed ORs <1.0, the overall estimate was nonsignificant and, as such, did not formally validate the findings in the Norwegian cohort. Conclusion: The APOBEC3A/B deletion polymorphism is associated with a decreased risk of endometrial cancer in the Norwegian population. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Mutation of GATA3 in human breast tumors

Author

Usary, Jerry, Llaca, Victor, Karaca, Gamze, Presswala, Shafaq, Karaca, Mehmet, He, Xiaping, Langerød, Anita, Kåresen, Rolf, Oh, Daniel S, Dressler, Lynn G, Lønning, Per E, Strausberg, Robert L, Chanock, Stephen, Børresen-Dale, Anne-Lise, and Perou, Charles M

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results